APDS

News

First drug for rare disease APDS cleared for NHS use

Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat APDS, an ultra-rare immunodeficiency disorder.

News

Pharming brings first drug for rare disease APDS to US

Joenja will launch in April and could make upwards of $200m a year in sales, say analysts.

Patients

pharmaphorum podcast Episode 234, Amy Bucher, Lirio

Delivering the right behavioural ingredients for the moment,...

Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks